Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

Rhea-AI Summary

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (Nasdaq: SNSE), an immuno-oncology firm, announced that its CEO, John Celebi, will participate in a panel on 'Novel Approaches in Immunotherapy' at the Cantor Fitzgerald's Future of Oncology Virtual Symposium on April 3rd at 10:00 a.m. ET.

Sensei Biotherapeutics focuses on developing next-generation therapeutics for cancer patients using its TMAb™ platform. The lead candidate is SNS-101, targeting VISTA in the tumor microenvironment. Other candidates include SNS-102 and SNS-103, which target VSIG-4 and ENTPDase1, respectively. For more details, visit www.senseibio.com.

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that John Celebi, president and chief executive officer, will participate in a panel titled ‘Novel Approaches in Immunotherapy’ at Cantor Fitzgerald’s Future of Oncology Virtual Symposium on Monday, April 3^rd at 10.00 a.m. ET.

About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn. 

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What is the date of Sensei Biotherapeutics' participation in the Cantor Fitzgerald symposium?

Sensei Biotherapeutics will participate in the Cantor Fitzgerald Future of Oncology Virtual Symposium on April 3, 2023.

Who will represent Sensei Biotherapeutics at the oncology symposium?

John Celebi, the president and CEO of Sensei Biotherapeutics, will represent the company at the symposium.

What is the main focus of Sensei Biotherapeutics?

Sensei Biotherapeutics focuses on the discovery and development of next-generation therapeutics for cancer patients.

What is SNS-101 developed by Sensei Biotherapeutics?

SNS-101 is a conditionally active antibody designed to block VISTA in the tumor microenvironment.

What other candidates are being developed by Sensei Biotherapeutics?

Sensei Biotherapeutics is also developing SNS-102 and SNS-103, targeting VSIG-4 and ENTPDase1, respectively.

What is the ticker symbol for Sensei Biotherapeutics?

The ticker symbol for Sensei Biotherapeutics is SNSE.